カテゴリ： GlobalData, アメリカ, 企業調査

Incyte Corp (INCY)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Incyte Corp (INCY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9974
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. JAKAFI is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp (INCY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13
Private Equity 14
TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14
Partnerships 15
Incyte and Foundation Medicine Enter into Agreement 15
Immunovaccine Enters into Agreement with Incyte 16
Incyte and Syros Pharma Enter into Agreement 17
AstraZeneca and MedImmune Expands Agreement with Incyte 18
Bristol-Myers Squibb and Incyte Enter into Agreement 19
Incyte Enters into Research Agreement with Abramson Cancer Center 20
Incyte Enters into Distribution Agreement with GENESIS Pharma 21
Incyte Enters into Agreement with Moffitt Cancer Center 22
Incyte Enters into Agreement with AstraZeneca 23
Incyte Extends Partnership with Merck 24
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25
Licensing Agreements 26
Incyte Enters into Licensing Agreement with MacroGenics 26
Incyte Enters into Licensing Agreement with Calithera Biosciences 27
Incyte Enters into Licensing Agreement with Merus 29
Incyte Amends Licensing Agreement with ARIAD Pharma 31
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32
Incyte Amends Licensing Agreement with Agenus 33
Equity Offering 35
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36
Incyte Raises USD650 Million in Public Offering of Shares 37
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38
Agenus Raises USD35 Million in Private Placement of Common Stock 40
Debt Offering 41
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 41
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 43
Acquisition 45
Gilead Sciences May Acquire Incyte 45
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46
Incyte Corp – Key Competitors 48
Incyte Corp – Key Employees 49
Incyte Corp – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Financial Announcements 51
Sep 30, 2018: Incyte reports 2018 third quarter and nine month financial results and provides updates on key clinical programs 51
Jul 31, 2018: Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs 57
May 01, 2018: Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs 60
Feb 15, 2018: Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs 63
Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 66
May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 68
Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 70
Corporate Communications 73
Sep 06, 2018: Incyte announces Chief Financial Officer David Gryska to retire at the End of 2018 73
Oct 30, 2017: Incyte Names New Member to Its Board of Directors 74
Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 75
Product News 76
06/21/2018: Incyte to Present Data on INCB54828 at 2018 Investor and Analyst Event 76
04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 77
03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 78
03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79
Clinical Trials 80
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 80
Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 81
Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 82
Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 83
Mar 28, 2017: Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13
TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14
Incyte and Foundation Medicine Enter into Agreement 15
Immunovaccine Enters into Agreement with Incyte 16
Incyte and Syros Pharma Enter into Agreement 17
AstraZeneca and MedImmune Expands Agreement with Incyte 18
Bristol-Myers Squibb and Incyte Enter into Agreement 19
Incyte Enters into Research Agreement with Abramson Cancer Center 20
Incyte Enters into Distribution Agreement with GENESIS Pharma 21
Incyte Enters into Agreement with Moffitt Cancer Center 22
Incyte Enters into Agreement with AstraZeneca 23
Incyte Extends Partnership with Merck 24
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25
Incyte Enters into Licensing Agreement with MacroGenics 26
Incyte Enters into Licensing Agreement with Calithera Biosciences 27
Incyte Enters into Licensing Agreement with Merus 29
Incyte Amends Licensing Agreement with ARIAD Pharma 31
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32
Incyte Amends Licensing Agreement with Agenus 33
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36
Incyte Raises USD650 Million in Public Offering of Shares 37
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38
Agenus Raises USD35 Million in Private Placement of Common Stock 40
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 41
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 43
Gilead Sciences May Acquire Incyte 45
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46
Incyte Corp, Key Competitors 48
Incyte Corp, Key Employees 49
Incyte Corp, Subsidiaries 50

List of Figures
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Incyte Corp (INCY)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • KitCheck Inc：医療機器：M&Aディール及び事業提携情報
    Summary KitCheck Inc (KitCheck) is a provider of automated hospital pharmacy kit processing and medication tracking software solution. The company’s Kit Check is an automated medication tray management system based on scalable cloud software platform uses RFID tags to track each medication that help …
  • Apoteket AB：企業の戦略的SWOT分析
    Apoteket AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Xinjiang Goldwind Science & Technology Co Ltd (002202)：企業の財務・戦略的SWOT分析
    Xinjiang Goldwind Science & Technology Co Ltd (002202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Owens & Minor Inc (OMI)-製薬・医療分野：企業M&A・提携分析
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • Ridley USA Inc：企業の戦略的SWOT分析
    Ridley USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Inspire Medical Systems Inc-医療機器分野：企業M&A・提携分析
    Summary Inspire Medical Systems Inc (Inspire) is a medical device company that manufactures and markets healthcare implants. The company provides implanted neurostimulation device. Its product is used for treatment of obstructive sleep apnea. Inspire uses neurostimulation technologies. The company’s …
  • Biovista Inc-製薬・医療分野：企業M&A・提携分析
    Summary Biovista Inc (Biovista) is a drug development company that provides COSS platform technology support in uncovering non-obvious correlations between drugs. The company’s products are used for the treatment of neurodegenerative diseases, epilepsy, oncology and orphan diseases. It offers servic …
  • C&C Group plc：戦略・SWOT・企業財務分析
    C&C Group plc - Strategy, SWOT and Corporate Finance Report Summary C&C Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • National Institute on Drug Abuse：製薬・医療：M&Aディール及び事業提携情報
    Summary National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine …
  • Saudi Arabian Fertilizers Co (2020)：企業の財務・戦略的SWOT分析
    Saudi Arabian Fertilizers Co (2020) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fibrocell Science Inc (FCSC)：医療機器：M&Aディール及び事業提携情報
    Summary Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company’s product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic …
  • Penumbra Inc (PEN)：企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • WEG SA：戦略・SWOT・企業財務分析
    WEG SA - Strategy, SWOT and Corporate Finance Report Summary WEG SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • TransMontaigne Partners LP (TLP)：企業の財務・戦略的SWOT分析
    Summary TransMontaigne Partners LP (TLP), a subsidiary of TransMontaigne GP LLC is an energy infrastructure service provider that offers integrated terminaling, transportation, and storage services. The company distributes and transports crude oil, chemicals, petroleum products, fertilizers, and oth …
  • Xencor Inc (XNCR)：企業の財務・戦略的SWOT分析
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • Dar Al Dawa Development & Investment Co Ltd (DADI)：企業の財務・戦略的SWOT分析
    Dar Al Dawa Development & Investment Co Ltd (DADI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Ultra Petroleum Corp.：企業の戦略・SWOT・財務分析
    Ultra Petroleum Corp. - Strategy, SWOT and Corporate Finance Report Summary Ultra Petroleum Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Lii Hen Industries Bhd：企業の戦略・SWOT・財務情報
    Lii Hen Industries Bhd - Strategy, SWOT and Corporate Finance Report Summary Lii Hen Industries Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Helmerich & Payne Inc (HP)：企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Apartment Investment and Management Co：企業の戦略・SWOT・財務情報
    Apartment Investment and Management Co - Strategy, SWOT and Corporate Finance Report Summary Apartment Investment and Management Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆